BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+^™ for Breast Cancer

BriaCell Therapeutics announced a collaboration with Memorial Sloan Kettering Cancer Center’s Therapeutics Accelerator Cohort program to accelerate the clinical development of Bria-OTS+, BriaCell’s next generation personalized off-the-shelf immunotherapy, for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers.